MX2014001019A - Dominios variables singulares anti-vgf fusionados con dominios de fc. - Google Patents

Dominios variables singulares anti-vgf fusionados con dominios de fc.

Info

Publication number
MX2014001019A
MX2014001019A MX2014001019A MX2014001019A MX2014001019A MX 2014001019 A MX2014001019 A MX 2014001019A MX 2014001019 A MX2014001019 A MX 2014001019A MX 2014001019 A MX2014001019 A MX 2014001019A MX 2014001019 A MX2014001019 A MX 2014001019A
Authority
MX
Mexico
Prior art keywords
domains
antigen binding
vegf
dimers
single variable
Prior art date
Application number
MX2014001019A
Other languages
English (en)
Inventor
Alan Peter Lewis
Claire Ashman
Ian Richard Catchpole
Zoe Hughes-Thomas
Michael Steward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014001019(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2014001019A publication Critical patent/MX2014001019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención está dirigida a construcciones de unión de antígeno que comprenden uno o dos dominios de unión de epítope separados por una región Fc de una sola cadena de un anticuerpo, en donde cada dominio de unión de epítope es capaz de unirse a VEGF; a dímeros que comprenden dos construcciones de unión de antígeno de la invención; composiciones farmacéuticas que comprenden dichos dímeros, y su uso en el tratamiento de enfermedades asociadas con la señalización de VEGF, tales como edema macular diabético (DME), degeneración macular húmeda asociada con la edad (AMD húmeda), retinopatía diabética, oclusión de la vena retinal (RVO) y neovascularización corneal; y secuencias de polinucleótido que codifican dichas construcciones de unión de antígeno.
MX2014001019A 2011-07-27 2012-07-25 Dominios variables singulares anti-vgf fusionados con dominios de fc. MX2014001019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512138P 2011-07-27 2011-07-27
PCT/EP2012/064632 WO2013014208A2 (en) 2011-07-27 2012-07-25 Antigen binding constructs

Publications (1)

Publication Number Publication Date
MX2014001019A true MX2014001019A (es) 2014-05-13

Family

ID=46579044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001019A MX2014001019A (es) 2011-07-27 2012-07-25 Dominios variables singulares anti-vgf fusionados con dominios de fc.

Country Status (18)

Country Link
US (2) US9499612B2 (es)
EP (1) EP2736925A2 (es)
JP (1) JP5987057B2 (es)
KR (1) KR101632620B1 (es)
CN (1) CN103842380A (es)
AU (1) AU2012288846B2 (es)
BR (1) BR112014001855A2 (es)
CA (1) CA2842099A1 (es)
CL (1) CL2014000204A1 (es)
CO (1) CO7020847A2 (es)
CR (1) CR20140047A (es)
DO (1) DOP2014000017A (es)
EA (1) EA028886B1 (es)
HK (1) HK1198446A1 (es)
MA (1) MA35352B1 (es)
MX (1) MX2014001019A (es)
PE (1) PE20141659A1 (es)
WO (1) WO2013014208A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
EP2723769B2 (en) 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107172879B (zh) 2014-11-10 2021-11-05 豪夫迈·罗氏有限公司 抗白细胞介素-33抗体及其用途
TW201643179A (zh) 2015-03-11 2016-12-16 葛蘭素史克智慧財產發展有限公司 Ｔｓｌｐ結合蛋白
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
US20170267768A1 (en) * 2016-03-16 2017-09-21 The Regents Of The University Of California Protein A Binding Polypeptides, Anti-EphA2 Antibodies and Methods of Use Thereof
WO2017175145A1 (en) 2016-04-05 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
JP2020514301A (ja) * 2017-01-06 2020-05-21 モメンタ ファーマシューティカルズ インコーポレイテッド 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
CN109021103B (zh) * 2017-06-12 2022-08-23 上海睿智化学研究有限公司 抗人血管内皮生长因子的抗体及其制备方法和应用
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022011156A (es) 2020-03-13 2022-10-13 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos.
KR20230165901A (ko) * 2021-02-19 2023-12-05 도트바이오 피티이. 리미티드 Vegfa-결합 분자
WO2023014892A1 (en) * 2021-08-04 2023-02-09 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders
CN118043350A (zh) * 2021-08-13 2024-05-14 信达生物制药(苏州)有限公司 抗vegf a和vegf c双特异性抗体及其用途
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
WO2024055995A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB2361237A (en) 1998-05-13 2001-10-17 Diversys Ltd Selection system
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
WO2001057065A2 (en) 2000-02-03 2001-08-09 Domantis Limited Combinatorial protein domains
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN101039959A (zh) * 2004-06-30 2007-09-19 杜门蒂斯有限公司 用于治疗炎性疾病的组合物和方法
EP1776385A1 (en) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2007011041A1 (ja) 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901494A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
CN104650235A (zh) 2007-11-30 2015-05-27 葛兰素集团有限公司 抗原结合构建体
JP2011506396A (ja) * 2007-12-13 2011-03-03 グラクソ グループ リミテッド 肺送達用組成物
HUE028536T2 (en) * 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
WO2010097385A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2435075A2 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
WO2011063348A1 (en) * 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質

Also Published As

Publication number Publication date
CL2014000204A1 (es) 2014-07-25
HK1198446A1 (en) 2015-04-24
EP2736925A2 (en) 2014-06-04
KR20140041908A (ko) 2014-04-04
AU2012288846A1 (en) 2014-02-06
PE20141659A1 (es) 2014-11-21
BR112014001855A2 (pt) 2017-02-21
JP2014523746A (ja) 2014-09-18
MA35352B1 (fr) 2014-08-01
CN103842380A (zh) 2014-06-04
EA201391812A1 (ru) 2014-06-30
WO2013014208A3 (en) 2013-05-10
CR20140047A (es) 2014-03-24
WO2013014208A2 (en) 2013-01-31
DOP2014000017A (es) 2014-04-30
JP5987057B2 (ja) 2016-09-06
US20140205604A1 (en) 2014-07-24
CO7020847A2 (es) 2014-08-11
EA028886B1 (ru) 2018-01-31
US9499612B2 (en) 2016-11-22
CA2842099A1 (en) 2013-01-31
AU2012288846B2 (en) 2016-05-19
KR101632620B1 (ko) 2016-06-23
US20170029494A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
MX2014001019A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc.
HRP20210517T1 (hr) Pripravci i postupci za protutijela usmjerena na epo
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
BR112015009961A2 (pt) imunoglobinas anti-vegf/dll4 com duplo domínio variável e uso destas
NZ706377A (en) Il-6 antagonists and uses thereof
MX343440B (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
EA201890143A2 (ru) Антитела против pdgfr-бета и их применения
NZ743815A (en) Tetravalent anti-psgl-1 antibodies and uses thereof
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
EA201791005A1 (ru) Улучшенные антитела против il-6
WO2014062659A3 (en) Methods of treating ocular diseases
MA40182A (fr) NOUVEL ANTICORPS ANTI-Tie2 HUMAIN
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
MX2018000869A (es) Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
EA201501061A1 (ru) Антитела к igf-1r с элиминированной способностью связываться с fcrn и их применение для лечения сосудистых глазных заболеваний
TN2013000389A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
WO2015073743A3 (en) Methods using monovalent antigen binding constructs targeting her2
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ